192 related articles for article (PubMed ID: 22366560)
1. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth.
Lamers F; Schild L; den Hartog IJ; Ebus ME; Westerhout EM; Ora I; Koster J; Versteeg R; Caron HN; Molenaar JJ
Eur J Cancer; 2012 Nov; 48(16):3093-103. PubMed ID: 22366560
[TBL] [Abstract][Full Text] [Related]
2. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.
Salm F; Cwiek P; Ghosal A; Lucia Buccarello A; Largey F; Wotzkow C; Höland K; Styp-Rekowska B; Djonov V; Zlobec I; Bodmer N; Gross N; Westermann F; Schäfer SC; Arcaro A
Oncogene; 2013 Aug; 32(34):3944-53. PubMed ID: 23027129
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
4. Interstitial chemotherapy with ricin-loaded thermosensitive hydrogel in pancreatic cancer xenograft.
Chen ZK; Lin LW; Weng XH; Xue ES; Lin YH
Hepatobiliary Pancreat Dis Int; 2009 Aug; 8(4):418-23. PubMed ID: 19666413
[TBL] [Abstract][Full Text] [Related]
5. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
6. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
7. Norcantharidin enhances ABT-263-mediated anticancer activity in neuroblastoma cells by upregulation of Noxa.
Wang X; Gu Z; Li G; Zhang S; Cao Z; Yang Z; Liu G
Oncol Rep; 2014 Aug; 32(2):716-22. PubMed ID: 24891300
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
[TBL] [Abstract][Full Text] [Related]
9. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
[TBL] [Abstract][Full Text] [Related]
10. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
11. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
[TBL] [Abstract][Full Text] [Related]
13. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
Bender A; Opel D; Naumann I; Kappler R; Friedman L; von Schweinitz D; Debatin KM; Fulda S
Oncogene; 2011 Jan; 30(4):494-503. PubMed ID: 20856197
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.
Halatsch ME; Kast RE; Dwucet A; Hlavac M; Heiland T; Westhoff MA; Debatin KM; Wirtz CR; Siegelin MD; Karpel-Massler G
Br J Pharmacol; 2019 Sep; 176(18):3681-3694. PubMed ID: 31222722
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Sasaki N; Kuroda J; Nagoshi H; Yamamoto M; Kobayashi S; Tsutsumi Y; Kobayashi T; Shimura Y; Matsumoto Y; Taki T; Nishida K; Horiike S; Akao Y; Taniwaki M
Exp Hematol; 2011 Aug; 39(8):817-28.e1. PubMed ID: 21640157
[TBL] [Abstract][Full Text] [Related]
16. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
17. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
Wang G; Zhan Y; Wang H; Li W
Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880
[TBL] [Abstract][Full Text] [Related]
18. Aluminum-maltolate induces apoptosis and necrosis in neuro-2a cells: potential role for p53 signaling.
Johnson VJ; Kim SH; Sharma RP
Toxicol Sci; 2005 Feb; 83(2):329-39. PubMed ID: 15537749
[TBL] [Abstract][Full Text] [Related]
19. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
[TBL] [Abstract][Full Text] [Related]
20. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]